Table 5 Incremental cost effectiveness ratios and cost-effectiveness relative to no intervention for individual participants in a prevention programme
Method of identifying participants | Intervention | Incremental cost effectiveness ratio (ICER) (relative to next best intervention) | Cost effectiveness ratio (CER) (relative to no intervention) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Incremental cost (£, 2015) | Incremental effect (QALYs) | ICER (£/QALY) | Probability ICER < £20,000/QALY | Cost vs no intervention (£, 2015) | Effect vs no intervention (QALYs) | CER (£/QALY) | Probability CER < £20,000/QALY | ||
IGT | No intervention | - | - | - | - | - | - | - | - |
Low-intensity lifestyle | 3 | 0.06 | 44 | 98.19% | 3 | 0.06 | 44.33 | 98.19% | |
Metformin | Subject to extended dominance | 367 | 0.07 | 5,224 | 75.86% | ||||
High-intensity lifestyle | 649 | 0.18 | 3,707 | 74.58% | 652 | 0.23 | 2,775 | 80.5% | |
IFG | No intervention | - | - | - | - | - | - | - | - |
Low-intensity lifestyle | 11 | 0.06 | 195 | 98.5% | 11 | 0.06 | 195 | 98.5% | |
Metformin | Subject to extended dominance | 479 | 0.07 | 6,842 | 76.28% | ||||
High-intensity lifestyle | 1,012 | 0.09 | 11,219 | 75.09% | 1,023 | 0.15 | 6,820 | 81.44% | |
HbA1c | No intervention | - | - | - | - | - | - | - | - |
Low-intensity lifestyle | 11 | 0.06 | 186 | 97.79% | 11 | 0.06 | 186 | 97.79% | |
Metformin | 28 | 0.05 | 600 | 50.40% | 39 | 0.10 | 372 | 77.89% | |
High-intensity lifestyle | 1,032 | 0.04 | 25,481 | 40.38% | 1,071 | 0.15 | 7,376 | 71.28% | |